Acyclovir fleximer (Kowloon)

Acyclovir fleximer

Fleximers are different series of flexible, or ?split? purine base analogues designed to learn how nucleobase flexibility affects the recognition, binding, and activity of nucleoside(tide) analogues. There is a purine base scaffold in the fleximers. With this purine base scaffold, the imidazole and pyrimidine moieties are combined by a single carbon-carbon bond, rather than being ?fused? as is typical for the purines. In previous reports, a number of novel fleximers have been screened, and these fleximers can combine the flex-base motif with the flexible acyclic sugar scaffold of the FDA-approved drug acyclovir (serves as a polymerase inhibitor). Studies demonstrated that these fleximers can inhibit HCoV-NL63 and MERS-CoV replication in cell culture. However, it is still unknown how these novel analogues disrupt viral replication. In summary, acyclovir fleximers for SARS-CoV-2 are a group of promising drug candidates for the new drug discovery. For more: https://sars-cov-2.creative-biolabs.com/acyclovir-fleximer-for-the-treatment-of-sars-cov2.htm